Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Equal-Weight rating on Pacific Biosciences (PACB) and lowers the price target from $3 to $2.
May 10, 2024 | 7:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained its Equal-Weight rating on Pacific Biosciences but reduced the price target from $3 to $2, indicating a cautious outlook.
The reduction in price target by a reputable analyst like Barclays suggests a bearish outlook on the stock, potentially leading to short-term negative sentiment among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100